Hualan Biological Vaccine Inc. (SHE:301207)

Market Cap	10.72B +14.5%
Revenue (ttm)	1.20B +7.8%
Net Income	187.51M -6.1%
EPS	0.32 -5.8%
Shares Out	595.00M
PE Ratio	57.19
Forward PE	50.06
Dividend	1.60 (8.88%)
Ex-Dividend Date	Oct 27, 2025

Volume	5,488,601
Open	18.96
Previous Close	17.80
Day's Range	17.75 - 18.96
52-Week Range	15.78 - 27.88
Beta	0.69
Analysts	Strong Buy
Price Target	26.84 (+48.95%)
Earnings Date	Aug 26, 2026

About Hualan Biological Vaccine

Hualan Biological Vaccine Inc. engages in the research and development, production, and sale of vaccines and genetically engineered biological products in China. The company’s main products include influenza virus split vaccine, quadrivalent influenza virus split vaccine, quadrivalent influenza virus split vaccine (pediatric formulation), H1N1 influenza A virus split vaccine, ACYW135 group meningococcal polysaccharide vaccine, recombinant hepatitis B vaccine (Hansenula polymorpha), group A and C meningococcal polysaccharide vaccine, freeze-drie...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 708
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301207

Financial Performance

In 2025, Hualan Biological Vaccine's revenue was 1.20 billion, an increase of 6.62% compared to the previous year's 1.13 billion. Earnings were 182.92 million, a decrease of -10.99%.